IBD-Associated Arthritis News

Targeted therapies for active inflammatory arthritis should be started “without delay” for patients with cancer in remission, according to new EULAR points to consider published in Annals of the Rheumatic Diseases.

WASHINGTON — Among patients with systemic autoimmune rheumatic diseases, circulating interleukin-18 levels were lower in those with long COVID vs. those without, according to data presented at ACR Convergence 2024.

SAN DIEGO — New imaging technologies, and improved use of the ones currently available, may move rheumatology closer to precision medicine in inflammatory arthritis, according to a speaker at the 2024 Congress of Clinical Rheumatology West.

The ability to view laboratory results, track symptoms and sharing them with a provider were rated as the most useful potential app functions by patients with rheumatic and musculoskeletal diseases, according to data.

The common consensus for some time has been that the prevalence of autoimmunity and autoimmune diseases has been on the rise.

Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.

Poverty and chronic inflammation together may have a “synergistic” impact leading to higher all-cause mortality, including a 127% increased heart disease mortality risk and a 196% higher risk for cancer mortality, according to data.

The first 10 drugs eligible for price negotiation through Medicare includes etanercept and ustekinumab, biologic therapies commonly used to treat patients with rheumatic diseases, the Biden administration announced.

The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.